Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mayne Pharma Group ( (AU:MYX) ) has shared an update.
Mayne Pharma Group Limited announced the cessation of certain securities, specifically 529,129 performance rights and 695,322 options, due to the expiry of options or other convertible securities without exercise or conversion as of September 30, 2025. This cessation may impact the company’s capital structure and could have implications for stakeholders, as it reflects adjustments in the company’s financial instruments and potential changes in shareholder value.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceutical products. The company is known for its expertise in drug delivery systems and its market focus includes both domestic and international markets.
YTD Price Performance: 16.10%
Average Trading Volume: 283,214
Technical Sentiment Signal: Buy
Current Market Cap: A$468.8M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.